HRP20250864T1 - Kristalni oblici p2x3 modulatora metil (s)‑2‑((2‑(2,6‑difluoro‑4‑(metilkarbamoil)fenil)‑7‑metilimidazo[1,2‑a] piridin‑3‑il)metil)morfolin‑4‑karboksilata - Google Patents
Kristalni oblici p2x3 modulatora metil (s)‑2‑((2‑(2,6‑difluoro‑4‑(metilkarbamoil)fenil)‑7‑metilimidazo[1,2‑a] piridin‑3‑il)metil)morfolin‑4‑karboksilataInfo
- Publication number
- HRP20250864T1 HRP20250864T1 HRP20250864TT HRP20250864T HRP20250864T1 HR P20250864 T1 HRP20250864 T1 HR P20250864T1 HR P20250864T T HRP20250864T T HR P20250864TT HR P20250864 T HRP20250864 T HR P20250864T HR P20250864 T1 HRP20250864 T1 HR P20250864T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- theta
- methyl
- type
- form according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760307P | 2018-11-13 | 2018-11-13 | |
| EP19884611.5A EP3880678B1 (en) | 2018-11-13 | 2019-11-12 | Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate |
| PCT/IB2019/001199 WO2020099923A1 (en) | 2018-11-13 | 2019-11-12 | Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250864T1 true HRP20250864T1 (hr) | 2025-09-26 |
Family
ID=70732059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250864TT HRP20250864T1 (hr) | 2018-11-13 | 2019-11-12 | Kristalni oblici p2x3 modulatora metil (s)‑2‑((2‑(2,6‑difluoro‑4‑(metilkarbamoil)fenil)‑7‑metilimidazo[1,2‑a] piridin‑3‑il)metil)morfolin‑4‑karboksilata |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220002292A1 (https=) |
| EP (1) | EP3880678B1 (https=) |
| JP (2) | JP2022507251A (https=) |
| CN (1) | CN113302191A (https=) |
| AU (1) | AU2019378161B2 (https=) |
| CA (1) | CA3119711A1 (https=) |
| DK (1) | DK3880678T3 (https=) |
| ES (1) | ES3033466T3 (https=) |
| FI (1) | FI3880678T3 (https=) |
| HR (1) | HRP20250864T1 (https=) |
| HU (1) | HUE071480T2 (https=) |
| IL (1) | IL282996A (https=) |
| LT (1) | LT3880678T (https=) |
| MX (1) | MX2021005424A (https=) |
| PL (1) | PL3880678T3 (https=) |
| PT (1) | PT3880678T (https=) |
| RS (1) | RS66922B1 (https=) |
| SI (1) | SI3880678T1 (https=) |
| SM (1) | SMT202500237T1 (https=) |
| WO (1) | WO2020099923A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL282087B2 (en) * | 2018-10-10 | 2025-11-01 | Bellus Health Cough Inc | 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus |
| JP7578602B2 (ja) * | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３修飾薬での治療 |
| CN114085220B (zh) * | 2020-06-22 | 2023-06-16 | 上海海雁医药科技有限公司 | 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途 |
| EP4169921A4 (en) * | 2020-06-29 | 2024-06-19 | Wuhan LL Science and Technology Development Co., Ltd. | Crystalline form of heterocyclic compound, preparation method therefor and application thereof |
| WO2022161462A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| WO2025140586A1 (zh) * | 2023-12-29 | 2025-07-03 | 人福医药集团股份公司 | 一种p2x3受体拮抗剂的固体分散体及其制备工艺 |
| WO2025191081A1 (en) | 2024-03-15 | 2025-09-18 | Glaxosmithkline Intellectual Property (No.3) Limited | Crystalline form of camlipixant |
| WO2025210540A1 (en) | 2024-04-02 | 2025-10-09 | Assia Chemical Industries Ltd. | Solid state forms of camlipixant and process for preparation thereof |
| WO2026022326A1 (en) * | 2024-07-25 | 2026-01-29 | Glaxosmithkline Intellectual Property (No.3) Limited | P2x3 antagonist formulation |
| JP2026049185A (ja) | 2024-09-06 | 2026-03-18 | キヤノン株式会社 | 撮像装置、撮像方法、及びコンピュータプログラム |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3381917T3 (da) * | 2013-01-31 | 2021-10-18 | Bellus Health Cough Inc | Imidazopyridinforbindelser og anvendelser deraf |
| US10111883B1 (en) | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
-
2019
- 2019-11-12 HR HRP20250864TT patent/HRP20250864T1/hr unknown
- 2019-11-12 FI FIEP19884611.5T patent/FI3880678T3/fi active
- 2019-11-12 EP EP19884611.5A patent/EP3880678B1/en active Active
- 2019-11-12 CN CN201980088914.9A patent/CN113302191A/zh active Pending
- 2019-11-12 US US17/292,663 patent/US20220002292A1/en active Pending
- 2019-11-12 ES ES19884611T patent/ES3033466T3/es active Active
- 2019-11-12 LT LTEPPCT/IB2019/001199T patent/LT3880678T/lt unknown
- 2019-11-12 PT PT198846115T patent/PT3880678T/pt unknown
- 2019-11-12 JP JP2021525726A patent/JP2022507251A/ja active Pending
- 2019-11-12 SI SI201930943T patent/SI3880678T1/sl unknown
- 2019-11-12 SM SM20250237T patent/SMT202500237T1/it unknown
- 2019-11-12 HU HUE19884611A patent/HUE071480T2/hu unknown
- 2019-11-12 WO PCT/IB2019/001199 patent/WO2020099923A1/en not_active Ceased
- 2019-11-12 CA CA3119711A patent/CA3119711A1/en active Pending
- 2019-11-12 MX MX2021005424A patent/MX2021005424A/es unknown
- 2019-11-12 AU AU2019378161A patent/AU2019378161B2/en active Active
- 2019-11-12 DK DK19884611.5T patent/DK3880678T3/da active
- 2019-11-12 PL PL19884611.5T patent/PL3880678T3/pl unknown
- 2019-11-12 RS RS20250594A patent/RS66922B1/sr unknown
-
2021
- 2021-05-06 IL IL282996A patent/IL282996A/en unknown
-
2024
- 2024-07-05 JP JP2024109053A patent/JP2024153665A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3880678T (pt) | 2025-05-22 |
| MX2021005424A (es) | 2021-06-15 |
| EP3880678A1 (en) | 2021-09-22 |
| CN113302191A (zh) | 2021-08-24 |
| JP2022507251A (ja) | 2022-01-18 |
| AU2019378161A1 (en) | 2021-06-03 |
| SI3880678T1 (sl) | 2025-08-29 |
| EP3880678A4 (en) | 2022-08-31 |
| AU2019378161B2 (en) | 2025-01-30 |
| LT3880678T (lt) | 2025-06-25 |
| EP3880678B1 (en) | 2025-05-07 |
| HUE071480T2 (hu) | 2025-08-28 |
| RS66922B1 (sr) | 2025-07-31 |
| WO2020099923A1 (en) | 2020-05-22 |
| FI3880678T3 (fi) | 2025-08-01 |
| IL282996A (en) | 2021-06-30 |
| US20220002292A1 (en) | 2022-01-06 |
| PL3880678T3 (pl) | 2025-08-04 |
| DK3880678T3 (da) | 2025-06-10 |
| JP2024153665A (ja) | 2024-10-29 |
| SMT202500237T1 (it) | 2025-07-22 |
| CA3119711A1 (en) | 2020-05-22 |
| ES3033466T3 (en) | 2025-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250864T1 (hr) | Kristalni oblici p2x3 modulatora metil (s)‑2‑((2‑(2,6‑difluoro‑4‑(metilkarbamoil)fenil)‑7‑metilimidazo[1,2‑a] piridin‑3‑il)metil)morfolin‑4‑karboksilata | |
| JP2022507251A5 (https=) | ||
| HRP20180970T1 (hr) | Policiklični lpa1 antagonist i njegove primjene | |
| IL291099B1 (en) | Aminothiazole compounds as C–KIT inhibitors | |
| HRP20240304T1 (hr) | Soli valbenazin dihidroklorida i njihovi polimorfi | |
| HRP20210252T1 (hr) | Heterociklički amidi kao inhibitori kinaze | |
| HRP20200280T1 (hr) | Derivati 1,3,4-oksadiazolsulfamida kao inhibitor histonske deacetilaze 6 i farmaceutski pripravak koji ih sadrži | |
| JP2013525433A5 (https=) | ||
| AR084824A1 (es) | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| HRP20210022T1 (hr) | Sol agonista opioidnog receptora (mor), fumaratna sol i kristalni oblik iste i postupak pripreme istih | |
| HRP20140611T1 (hr) | Inhibitori kinaze p70 s6 | |
| JP2018520205A5 (https=) | ||
| JP2014520108A5 (https=) | ||
| JP2016510796A5 (https=) | ||
| JP2015514061A5 (https=) | ||
| CN111655678A (zh) | 细胞凋亡信号调节激酶-1抑制剂及其应用 | |
| JP2011500621A5 (https=) | ||
| HRP20201644T1 (hr) | Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba | |
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| AU2021229414B2 (en) | Synthesis of novel EP4 antagonist and use in cancers and inflammations | |
| CN109311859A (zh) | 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物 | |
| JP2017513915A5 (https=) | ||
| JP2015510892A5 (https=) | ||
| HRP20192286T1 (hr) | Hidroksieitil sulfonat od ciklina ovisnog inhibitora kinaze proteina, njegov kristalni oblik, i postupak njegovog dobivanja | |
| JP2017527598A5 (https=) |